The marketing is slick, the claims are bold, and the before-and-after photos look impressive
Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
Whether working with busy professionals looking to recharge, athletes focused on recovery, or individuals committed to optimizing their health, she takes pride in creating a welcoming experience and helping each client feel cared for, confident, and supported
Lancet 397(10278):971984
It provides comprehensive support for research into metabolic pathways and their effects on health
Highly recommend if you want effective results